USPTO serial 79406277
CAELIMIR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- PEISECKI, MARK A
- Law office
- TMEG LAW OFFICE 105
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CAELIMIR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Software relating to the pharmaceutical field; bioinformatics software; healthcare software; software relating to the medical field; software relating to research, discovery and development of pharmaceuticals, therapeutics and/or diagnostics; electronic databases for capturing, storing, processing, evaluating and reproducing pharmaceutical data; all of the aforementioned goods whether or not including artificial intelligence. | ACTIVE | — |
| 042 | Providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing pharmaceutical data; software as a service (SaaS) featuring health monitoring software; software as a service (SaaS) featuring bioinformatics software; scientific computer programming services; pharmaceutical research and development; research and development of mRNA-based therapeutics; research and development of mRNA-based diagnostics; research and development of mRNA drugs; research and development in the field of microorganisms and cells; pharmaceutical products development; pharmaceutical product evaluation; testing of pharmaceuticals; development of gene-based medicines; laboratory research services relating to pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to research and development in the field of therapeutics; services for assessing the efficiency of pharmaceuticals; information technology services for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; chemical research and analysis services; medical and pharmacological research services; scientific research for medical purposes; research and development in the field of diagnostic preparations; genetic research; genetic mapping for scientific purposes; providing scientific information in the field of medical disorders and their treatment; biotechnological research; biochemical research and development; research and development of vaccines; pharmaceutical drug discovery and development services; all of the aforementioned services whether or not including artificial intelligence; platform as a Service (PaaS), Software as a Service (SaaS) and/or Data as a Service (DaaS) in relation to all the aforementioned services. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 22, 2026 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Oct 12, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 10, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 7, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 7, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 26, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 9, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 9, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 14, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 10, 2025 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 10, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 12, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 28, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 25, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 25, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 19, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 19, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 13, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 11, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 11, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 10, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |